Today, we take a look at Arrowhead Pharmaceuticals, Inc. ( ARWR ), who celebrated a transformational milestone on November 18 th with the approval of their lead drug candidate REDEMPLO™ (previously Plozasiran). REDEMPLO™ isI have a background in Risk Management, Finance, and Engineering and I write about what interests me. I hope you find it helpful - comments and questions are welcome.Analyst’s Disclosure:I/we have no stock, option or similar derivative position in any of the companies mentioned, and no pl ...

Core Insights - Arrowhead Pharmaceuticals, Inc. (ARWR) achieved a significant milestone with the approval of their lead drug candidate REDEMPLO™ (formerly known as Plozasiran) on November 18th [1] Company Summary - REDEMPLO™ represents a transformational advancement for Arrowhead Pharmaceuticals, marking a pivotal moment in the company's development pipeline [1]